Editorial: What to take from TREAT

Stephen B. Hanauer*

*Corresponding author for this work

Research output: Contribution to journalReview article

1 Scopus citations

Abstract

The TREAT Registry is an updated submission of the 5-year follow-up of Crohn's disease patients from community and academic centers in North America treated with or without infliximab. Over 6,000 patients were followed for risks of mortality and serious infections. Similar to data presented after nearly 2 years of follow-up, mortality was similar for infliximab-and other-treatment-only patients. Infliximab, corticosteroids and narcotics were associated with increased risks of serious infections. Data presented is similar from data reported for controlled trials and observational series in patients with inflammatory bowel disease and rheumatoid arthritis.

Original languageEnglish (US)
Pages (from-to)1423-1425
Number of pages3
JournalAmerican Journal of Gastroenterology
Volume107
Issue number9
DOIs
StatePublished - Sep 1 2012

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Editorial: What to take from TREAT'. Together they form a unique fingerprint.

  • Cite this